Novel Applications of Compounds for Treating Diverse Diseases

This inventive concept expands the therapeutic scope of compounds originally designed for treating coronavirus-associated diseases to address unmet needs in chronic obstructive pulmonary disease, skin conditions, gastrointestinal disorders, neurodegenerative diseases, and ocular diseases.

The original patent disclosed compounds effective against coronavirus-associated diseases. However, there remains a significant unmet need for effective treatments in various other disease areas. This inventive concept bridges this gap by applying the core technology to new therapeutic applications, leveraging the compounds' potential to address diverse diseases.

The inventive concept involves administering compounds represented by Formula I, wherein R1-R6 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and carbonyl, to patients suffering from chronic obstructive pulmonary disease, skin conditions, gastrointestinal disorders, neurodegenerative diseases, or ocular diseases. The compounds' unique properties enable them to interact with specific biological targets, leading to therapeutic benefits in these disease areas.

The novelty of this inventive concept lies in the unexpected application of the compounds to new disease areas, beyond their original indication for coronavirus-associated diseases. The inventive step is the recognition of the compounds' potential to address diverse diseases, which was not obvious from the original patent.

Alternative embodiments of this inventive concept may involve modifying the compounds' structures, adjusting dosing regimens, or combining them with other therapeutic agents to enhance efficacy or minimize side effects. Variations may include using different formulations, such as topical creams or oral tablets, to target specific disease areas.

This inventive concept has significant commercial potential, as it addresses unmet needs in multiple disease areas, including chronic obstructive pulmonary disease, skin conditions, gastrointestinal disorders, neurodegenerative diseases, and ocular diseases. The target market includes pharmaceutical companies, biotechnology firms, and research institutions seeking to develop innovative treatments for these diseases.